Insider filing · RCUS
II Robert C. Goeltz
Chief Financial Officer
profile →
Arcus Biosciences, Inc.
RCUS · Healthcare · 21 filings in 24 months
ticker →
II Robert C. Goeltz sold $279K of Arcus Biosciences (RCUS)
Executed Dec 16 2025, disclosed Dec 18 2025, 2 days later.
Value, as filed
$279K
12,662 sh across 2 lots
Executed
Dec 16 2025
the trade date, as filed
Disclosed
Dec 18 2025
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
IGII Robert C. Goeltz (Chief Financial Officer) filed 4 Form 4 reports in the trailing twelve months (0 purchases, 4 sales), most often in Arcus Biosciences, Inc. (RCUS). The largest single filing was $279K of RCUS (12,662 sh across 2 lots, as filed), executed Dec 16 2025.
The name
RCUSHealthcare · Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by II Robert C. Goeltz in RCUS
RCUSSALE
Arcus Biosciences, Inc.
$199K7,763 sh × $25.63
Exec May 11
Filed May 12 · 5:30 PM ET RCUSSALE Arcus Biosciences, Inc. $153K
6,552 sh × $23.38
Exec Dec 31 2025
Filed Jan 2 · 5:30 PM ET RCUSSALE Arcus Biosciences, Inc. $125K
5,000 sh × $25.00
Exec Nov 26 2025
Filed Nov 26 2025 · 5:30 PM ET RCUSSALE Arcus Biosciences, Inc. $100K
5,000 sh × $20.00
Exec Oct 28 2025
Filed Oct 29 2025 · 5:30 PM ET